Genmab (GMAB)
(Real Time Quote from BATS)
$28.42 USD
-0.41 (-1.42%)
Updated Jun 4, 2024 12:46 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Price, Consensus and EPS Surprise
GMAB 28.42 -0.41(-1.42%)
Will GMAB be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GMAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GMAB
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 17th
GMAB or TECH: Which Is the Better Value Stock Right Now?
HRMY or GMAB: Which Is the Better Value Stock Right Now?
Other News for GMAB
Genmab price target raised by $3 at Truist, here's why
Truist Financial Sticks to Their Buy Rating for Genmab (GMAB)
Genmab’s Acasunlimab Shows Promising Efficacy and Safety in NSCLC Treatment: Buy Rating Affirmed
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Genmab announces data from innovaTV 207 trial Part C